GLP-1 drugs and vision loss (NAION)

MDL 3163, E.D. Pa., Judge Karen S. Marston

Filings

Coordinated

Bellwethers

Settlement

Wind-down

Cases are centralized before one judge for pretrial work.

Updated Oct 21, 2026. Maintained by Jacob Malherbe.

New federal cases per week

New filings are counted on the Ozempic page, since both GLP-1 MDLs sit with the same judge. See the Ozempic page.

Litigation strength from 0 to 100. Last reviewed Jul 20, 2026. How it's set

Oct 21, 2026
New study
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies
Current obesity reports. Kounatidis DC et al.
PubMed (Curr Obes Rep)
Oct 19, 2026
News
Rutgers Study Links GLP-1 Drugs to Small Rise in Ischemic Optic Neuropathy in Adults With Type 2 Diabetes
findarticles
Oct 19, 2026
New study
Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review
Cureus. Muhsen J
PubMed (Cureus)

Get GLP-1 NAION developments at the top of the Monday briefing.

Depo-Provera and meningioma Coordinated (MDL or JCCP), 61 new cases in 7 days
Ozempic and GLP-1 stomach injuries Coordinated (MDL or JCCP), 35 new cases in 7 days
Suboxone and tooth decay Coordinated (MDL or JCCP), 2 new cases in 7 days
Dupixent and lymphoma (CTCL) Coordinated (MDL or JCCP), 2 new cases in 7 days

Mass Tort Ad Agency runs Meta tort campaigns for plaintiff firms and can show you what this tort's audience looks like.